BridgeBio Oncology shares tumble 24% as it narrows KRAS program focus
read at Endpoints ↗Negative
BridgeBio Oncology Therapeutics saw its stock drop sharply after announcing a strategic shift.
The company said it will scale back its broader pipeline to concentrate resources on its lead KRAS inhibitor, effectively narrowing the scope of its KRAS program.
The move led to a roughly 24% decline in the share price at market close on Wednesday, reflecting investor concerns about the reduced pipeline breadth.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BridgeBio Oncology slides as it tightens the scope of its KRAS program”
read at Endpoints ↗83 words · retrieved Sep 10
comments(0)
5-min edit window · permanent after that